Sergey Victorovich Suchkov
N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences · Russian Federation
Biography.
Dr. Sergey Suchkov was born in Astrakhan, Russia, into a family of medical doctors. He earned his MD from Astrakhan State Medical University in 1980 and his PhD from Sechenov University in 1985. He received advanced training at the NIH (Bethesda, USA), Wills Eye Hospital (Philadelphia, USA), and several British universities under the Royal Society for Immunology.
Dr. Suchkov has held numerous academic and leadership roles, including Director of the Division for Clinical Immunology & Immunobiotechnology at MONIKI, and Professor and Chair of the Department for Personalized & Precision Medicine at Sechenov University. He has also served as Vice-Director of the Institute for Biotech & Global Health at RosBioTech National University.
Currently, Dr. Suchkov is Professor of Medicine & Immunology and Director of the Center for Biodesign at the N.D. Zelinskii Institute of Organic Chemistry, Russian Academy of Sciences. He also serves as R&D Director at InMedStar (Russia–UAE) and Senior Scientific Advisor to the China Hong Kong Innovation International Business Association.
He is an active member of several international scientific organizations, including the New York Academy of Sciences, EPMA, ISPM, PMC, AMEE, ACS, AHA, ARVO, and ISER, and is Secretary General of the United Cultural Convention (UCC), Cambridge, UK.
Talks at earlier editions.
Personalized and Precision Medicine (PPM) as a unique healthcare model through bi-odesign-inspired bio- and chemical engineering applications to secure the human healthcare and biosafety: Engineering of biocatalysts - from evolution to creation
Abzymes (catalytic antibodies) as a generation of unique biomarkers, biocatalysts, potential targets and translational tools towards nanodesign-driven antibody engineering and precision medical practice: From magic bullet to precision weapon
Personalized and Precision Medicine (PPM) as a unique healthcare model via design-driven bio- and chemical engineering view of biotech
Antibody-proteases as a generation of unique biomarkers, potential targets and translational tools towards design-driven bio- and chemical engineering and personalized and precision medical practice
Personalized and Precision Medicine (PPM) as a unique healthcare model to be set up through biodesign-inspired biotech-driven translational applications and upgraded business marketing to secure the human healthcare, wellness and biosafety
Antibody-proteases as translational tools of the next-step generation to be applied for biotech, bioindustry and personalized and precision medical practice
Join the CCT 2027 delegation.
21–23 June 2027 · NH Villa Carpegna, Rome · In person and online